Shares of AstraZeneca tumbled on Monday after reports emerged that the British drugmaker had been in discussions with U.S. rival Bristol Myers Squibb about a potential combination that would create a company with a combined market value approaching $400 billion. AstraZeneca closed down roughly 9 percent, marking its largest single-day drop since 2020. Bristol Myers slipped by under 1 percent in early trade.
A person familiar with the matter confirmed that AstraZeneca and Bristol Myers had held talks, echoing earlier media reports. An AstraZeneca spokesperson declined to comment on the situation and Bristol Myers did not reply to a request for comment.
Market reaction and deal scale
The proposal under discussion would join one of Europe’s biggest pharmaceutical companies with a major United States competitor. On Friday, the two firms together had a market capitalisation near $400 billion, with AstraZeneca valued at about $264 billion and Bristol Myers at roughly $133 billion.
Market participants noted the size of the possible transaction and the immediate market reaction. For AstraZeneca shareholders, the shares’ near-9 percent fall represented a sharp rebuke from investors and analysts who question whether such a transformational move is necessary for the company.
Investor perspectives and concerns
Several investors and portfolio managers expressed doubts about the strategic rationale of combining the two businesses. Lucy Coutts, an investment director at JM Finn and an AstraZeneca shareholder, said the most obvious benefit for AstraZeneca would be a faster expansion of its U.S. footprint and sales. She added that, overall, holders of Bristol Myers stock would likely emerge as the main beneficiaries, and therefore the news would be received with coolness by AstraZeneca’s investor base.
Markus Manns, a portfolio manager at Union Investment and also an AstraZeneca shareholder, argued a combination "does not make strategic or financial sense" and warned it could unsettle what he described as a "well-run company with a full pipeline." Manns likened the rumoured move to the pharmaceutical industry's equivalent of a poorly conceived privatisation proposal, saying it would meet bewilderment among many market participants if true.
Lukas Leu, a portfolio manager at ATG Healthcare who holds AstraZeneca shares, acknowledged potential benefits such as margin improvement through cost synergies and deeper exposure in neuroscience and cell therapy. At the same time he stressed concerns about overlapping products and the broader effects of a mega-merger, stating that such deals can "kill innovation and agility" and would likely be growth-dilutive for AstraZeneca in the near term.
Strategic drivers and internal debate
One possible motivation for AstraZeneca to explore a deal is further expanding its presence in the United States, already the company’s largest market. AstraZeneca completed a direct listing on the New York Stock Exchange earlier this year. A merger with Bristol Myers would effectively mean a British company acquiring a significant U.S. pharmaceutical franchise.
Bristol Myers earns the majority of its revenue in the United States and maintains one of the industry's largest commercial footprints there. An unnamed portfolio manager at a top-20 AstraZeneca shareholder said that while increasing U.S. exposure might be attractive, it would be surprising given AstraZeneca management’s repeated endorsement of organic growth driven by research and development.
The same anonymous investor noted that consensus views tended to favour AstraZeneca’s pipeline strength and a lower degree of imminent patent expiries compared with Bristol Myers, and questioned why AstraZeneca would dilute its growth outlook by pursuing such a tie-up.
U.S. investment, revenue goals and manufacturing
In recent years AstraZeneca has invested heavily in U.S. manufacturing capacity and has worked to develop strong ties with the U.S. administration as it seeks to capture a larger share of the American market. The company has set an ambitious objective of generating half of its targeted $80 billion in annual revenue by 2030 from the United States. AstraZeneca reported roughly $59 billion in revenue last year.
Patent timing, oncology overlap and regulatory risk
Analysts and some investors noted additional drivers and constraints for a potential deal. Sean Conroy, an analyst at Shore Capital, said a combination could help AstraZeneca manage a patent cliff projected after 2030 and could also bolster its oncology franchise. Yet Conroy cautioned that investors generally view mega-mergers of this type with scepticism.
Overlap between Bristol Myers’ Opdivo and AstraZeneca’s Imfinzi - both cancer immunotherapies of the same type - could invite antitrust scrutiny and complicate regulatory approval for any combination.
Where this leaves investors
For now, market participants are left with confirmation that talks took place and a series of assessments from shareholders and managers questioning the move’s merits for AstraZeneca. The dramatic share move underscored investor unease about a potential strategic pivot away from the company’s recent, largely organic growth trajectory.
With officials from neither company providing substantive comment, uncertainty persists about whether discussions will progress or result in a definitive proposal.